4D Molecular Therapeutics Inc
FDMT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$790.56M
Close$
$2.31
79.5% downside
Current Fair Value
79.5% downsideOvervalued by 79.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $790.56 Million |
|---|---|
| Enterprise Value | $740.18 Million |
| Earnings per Share | $-2.42 |
| Beta | 2.74 |
| Outstanding Shares | 70,272,018 |
Return
| Return on Equity | -43.95% |
|---|---|
| Return on Assets | -36.37% |
| Return on Invested Capital | -44.26% |
Valuation & Multiples
| P/E Ratio | -4.38 |
|---|---|
| PEG | -13.08 |
| Price to Sales | 11.25 |
| Price to Book Ratio | 2.25 |
| Enterprise Value to Revenue | 8.32 |
| Enterprise Value to EBIT | -3.76 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.02
Consensus analyst estimateRevenue Estimate
$3.62 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-1.04
Consensus analyst estimateRevenue Estimate
$4.13 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 2.37% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.52%▼ 85.27% |
|---|---|
| Total Invested | $5.20M▼ 99.33% |
| Investors Holding | 26▼ 140.00% |
About 4D Molecular Therapeutics Inc
83 employees
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power o...